Læknablaðið - 15.10.1992, Side 26
334
LÆKNABLAÐIÐ
ÞAKKIR
Þakkir eru færðar Þorbirni Jónssyni og Jóni
Þorsteinssyni fyrir veitta aðstoð.
HEIMILDIR
1. Le Roy EC. Scleroderma, In: Kelley WN, Harris
D, Ruddy S, Sledge CB, eds. Textbook of
Rheumatology. 3rd ed. Philadelphia: WB Saunders,
1989.
2. Dunckley H, Gatenby PA, Hawkins B, et al.
Deficiency of C4A is a genetic determinant of
systemic lupus erythematosus in three etnic groups.
J Immunogenetics 1987; 14: 209-18.
3. Fielder AHL, Walport MJ, Batchelor JR, et al.
Family study of the major histocompatibility complex
in patients with systemic lupus erythematosus:
Importance of null alleles of C4A and C4B in
determining disease susceptibility. B Med J 1983;
286: 425-8.
4. Briggs DC, Welsh K, Pereira S, et al. A strong
association between null alleles at the C4 locus in
the major histocompatibility complex and systemic
sclerosis. Arthritis Rheum 1986; 29: 1274-7.
5. Pereira S, Black C, Welsh K, et al. Autoantibodies
and immunogenetics in 30 patients with systemic
sclerosis and their families. J Rheumatol 1987; 14:
760-5.
6. Schifferli JA, Peters DK. Complement, the immune-
complex lattice and the pathphysiology of
complement-deficiency syndromes. Lancet 1983; 2
(8356); 957-9.
7. Arason GJ, Harkin MS, Víkingsdóttir Þ, Valdimarsson
H. Development of enzyme immunoassays (EIA) for
measuring prevention of immune precipitation (PIP)
and solubilization of preformed complexes (SOL).
Scand J Immunol 1990; 32: 383.
8. Naama JK, Hamilton AO, Yeung-Laiwah AC, et
al. Prevention of immune precipitation by purified
classical pathway complement components. Ciin Exp
Immunol 1984; 58: 486-92.
9. Thompson RA, ed. Techniques in clinical
immunology. 2nd ed. Oxford, UK: Blackwell
Scientific Publication, 1981.
10. Kristín Traustadóttir. Obirtar heimildir.
11. Siminovitch K, Klein W, Pruzanski S, et al.
Circulating immune complexes in patients with
progressive systemic sclerosis. Arthritis Rheum 1982;
25: 1174-9.
12. Senaldi G. Lupoli S, Vergani D, et al. Activation of
the complement system in systemic sclerosis. Arthritis
Rheum 1989; 32: 1262-7.
13. Schifferli JA. Steiger G, Paccaud JG, et al. Difference
in the biological properties of the two forms of the
forth component of human complement (C4). Clin
Exp Immunol 1986; 63: 473-7.
14. Lachntan PJ, Walport MJ. Deficiency of the
effector mechanisms of the immune response and
autoimmunity. Autoimmunity and autoimmune
disease. Ciba Foundation Symposium 129. Chichester,
UK: A Wiley - interscience publication, 1987.